Research Analysts Issue Forecasts for Arvinas Q1 Earnings

Arvinas, Inc. (NASDAQ:ARVN) – Stock analysts at Wedbush increased their Q1 2025 earnings per share estimates for shares of Arvinas in a research report issued to clients and investors on Tuesday, February 11th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.93) per share for the quarter, up from their prior estimate of ($1.57). Wedbush has a “Outperform” rating and a $57.00 price objective on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. Wedbush also issued estimates for Arvinas’ Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.75) EPS, FY2026 earnings at ($3.17) EPS, FY2027 earnings at ($3.30) EPS and FY2028 earnings at ($3.51) EPS.

Several other equities research analysts have also recently commented on ARVN. Barclays dropped their target price on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Guggenheim restated a “buy” rating and issued a $57.00 price objective on shares of Arvinas in a report on Wednesday. BTIG Research began coverage on Arvinas in a report on Tuesday, December 10th. They set a “buy” rating and a $69.00 target price on the stock. Stephens began coverage on shares of Arvinas in a research report on Monday, November 18th. They issued an “overweight” rating and a $55.00 price target on the stock. Finally, Oppenheimer raised their price objective on shares of Arvinas from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $59.58.

Arvinas Trading Down 1.6 %

Shares of NASDAQ:ARVN opened at $17.67 on Friday. The company has a 50 day moving average of $19.04 and a 200-day moving average of $23.28. The firm has a market cap of $1.21 billion, a P/E ratio of -3.78 and a beta of 1.88. Arvinas has a twelve month low of $16.61 and a twelve month high of $53.08.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. During the same quarter in the prior year, the business posted ($2.53) earnings per share.

Institutional Trading of Arvinas

Several large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in Arvinas by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock valued at $57,371,000 after purchasing an additional 367,343 shares in the last quarter. Baker BROS. Advisors LP acquired a new stake in shares of Arvinas in the third quarter worth about $9,989,000. SG Americas Securities LLC boosted its stake in shares of Arvinas by 228.8% during the 4th quarter. SG Americas Securities LLC now owns 32,424 shares of the company’s stock worth $622,000 after acquiring an additional 22,564 shares in the last quarter. Wasatch Advisors LP increased its holdings in shares of Arvinas by 58.3% during the 3rd quarter. Wasatch Advisors LP now owns 435,943 shares of the company’s stock valued at $10,737,000 after acquiring an additional 160,510 shares during the last quarter. Finally, Barclays PLC lifted its holdings in Arvinas by 198.9% in the 3rd quarter. Barclays PLC now owns 121,699 shares of the company’s stock worth $2,998,000 after purchasing an additional 80,984 shares during the last quarter. 95.19% of the stock is owned by institutional investors and hedge funds.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.